Equity · Healthcare
Medline Inc. (MDLN) perpetual futures
MDLN perpetual futures on 1 crypto exchange – live perp price vs the stock, funding rate, open interest and where to trade MDLNUSDT.
Medline Inc. is a US-based manufacturer and distributor of medical and surgical products, serving hospitals, surgical centers, physician practices and nursing homes worldwide through its Medline Brand and Supply Chain Solutions divisions.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
1/1 live markets
Trading data
Perpetual market activity
Spot performance
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kNo sufficient depth · 0 of 1 venues absorb $10k
Too thin: MEXC
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
MDLNTightest spread
MDLNHighest volume
MDLNFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $44.20 |
| 12-month target range (low – high) | $37 – $55 |
| Ratings in the provider's consensus | 19 |
Price targets as of 2026-11-22
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 7 | 16 | 5 | 0 | 0 |
| Oct 2026 | 7 | 16 | 4 | 0 | 0 |
| Sep 2026 | 7 | 16 | 4 | 0 | 0 |
| Aug 2026 | 7 | 16 | 4 | 0 | 0 |
| Jul 2026 | 7 | 17 | 4 | 0 | 0 |
| Jun 2026 | 7 | 17 | 4 | 0 | 0 |
| May 2026 | 7 | 17 | 5 | 0 | 0 |
| Apr 2026 | 6 | 17 | 5 | 0 | 0 |
| Mar 2026 | 6 | 17 | 5 | 0 | 0 |
| Feb 2026 | 6 | 16 | 6 | 0 | 0 |
| Jan 2026 | 5 | 17 | 5 | 0 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
MDLN-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Carlyle Mozart Coinvestment Holdings converted 3,709,698 common units of Medline Holdings, LP into 3,709,698 Class A common shares and disposed of 3,709,698 Class B shares under other transactions on Nov 17-18, 2026.
Medline 10% owner CP Circle ML Holdco GP converted 3,709,698 Medline Holdings common units into 3,709,698 Class A shares and disposed of 3,709,698 Class B shares in two steps on Nov 17-18, 2026, all at $0.00.
Carlyle Group reported converting 3.71M Medline Holdings common units into 3.71M Class A shares and disposing of 3.71M Class B shares across two transactions on Nov 17-18, 2026.
TC Group Cayman Investment Holdings reported converting 3,709,698 Common Units of Medline Holdings, LP into 3,709,698 Class A Common Stock shares, with an equal number of Class B Common Stock shares disposed via J-Other, across two dates in November 2026.
Hellman & Friedman Capital Partners X (Parallel) reported disposing of 10.55M Class B common shares of Medline via a J-Other transaction at $0.00 per share, leaving 71.90M shares owned.
Filings
38 · Latest SEC filingsCarlyle Mozart Coinvestment Holdings converted 3,709,698 common units of Medline Holdings, LP into 3,709,698 Class A common shares and disposed of 3,709,698 Class B shares under other transactions on Nov 17-18, 2026.
Medline 10% owner CP Circle ML Holdco GP converted 3,709,698 Medline Holdings common units into 3,709,698 Class A shares and disposed of 3,709,698 Class B shares in two steps on Nov 17-18, 2026, all at $0.00.
Carlyle Group reported converting 3.71M Medline Holdings common units into 3.71M Class A shares and disposing of 3.71M Class B shares across two transactions on Nov 17-18, 2026.
TC Group Cayman Investment Holdings reported converting 3,709,698 Common Units of Medline Holdings, LP into 3,709,698 Class A Common Stock shares, with an equal number of Class B Common Stock shares disposed via J-Other, across two dates in November 2026.
Hellman & Friedman Capital Partners X (Parallel) reported disposing of 10.55M Class B common shares of Medline via a J-Other transaction at $0.00 per share, leaving 71.90M shares owned.
BX Mozart ML-1 Holdco L.P. converted 7,570,214 Common Units of Medline Holdings into 7,570,214 Class A shares and disposed of 7,570,214 Class B shares in related J-Other transactions, all at $0.00, across four dates on Nov 17-18, 2026.
BCP 8 Holdings Mozart Manager L.L.C. reported a conversion: 7.57M common units of Medline Holdings, LP became 7.57M Class A shares, while 7.57M Class B shares were disposed via other transactions; all at $0.00.
Medline officer Liberman Alexander M. exercised 1.27M incentive units into common units, had 472,398 units withheld for taxes, and received 798,680 Class B shares as awards.
Medline officer Laabs Amanda H. reported exercising 820,000 incentive units into common units at $15.09, receiving a 520,127-share Class B stock award, and 299,873 common units withheld for tax.
Medline CEO James M. Boyle reported option exercises converting 2.85M incentive units into 4.05M common units, with 1.54M units withheld for taxes, plus awards of 2.52M Class B shares.
Medline officer Golwas Douglas P exercised 463,211 Incentive Units into 1,411,808 Common Units (M-Exempt), received 895,512 Class B shares as awards, and had 516,296 Common Units withheld for taxes (F). No open-market buys or sales.
GIC Private Ltd sold 7.82M Class A shares of Medline Inc. at $35.15 per share, leaving it with 69.41M shares after the transaction.
GIC Private Ltd sold 20,678,630 shares of Medline Class A Common Stock across 5 open-market sales at $34.33-$35.78 per share.
Medline COO Stephen L Miller received an award of 87,667 Incentive Units of Medline Holdings, LP at $19.01 per unit on Aug 19, 2026, leaving him with 87,667 owned after the transaction.
Medline CEO James M. Boyle was awarded 764,252 Incentive Units of Medline Holdings, LP at $16.49 per unit on Aug 19, 2026, an A-Award grant rather than an open-market purchase. He held 764,252 units after.
GIC Private Ltd sold 1,600,000 shares of Medline Class A Common Stock in two open-market sales at $35.80, reducing its holdings to 22,802,482 shares.
GIC Private Ltd sold 590,284 shares of Medline Class A Common Stock at $35.58 on Aug 7, 2026, leaving 24.4M shares owned.
Transcripts
Earnings callsFY2026 Q32026-11-04
Earnings calls
AI summary
mixedMedline reported third quarter net sales of $7.9 billion, up 10% year over year, driven almost entirely by organic growth, with every segment and channel contributing. Adjusted EBITDA rose 12% to $1 billion with margins up 10 basis points to 12.2%, including an $81 million benefit from IEEPA tariff refunds and associated customer repayments. The company raised full year 2026 organic sales guidance for the third consecutive quarter to 10% to 10.5% from 9% to 10%, while reaffirming adjusted EBITDA guidance of $3.3 billion to $3.4 billion and expecting to land near the midpoint. For 2027, Medline provided a preliminary framework of high single digit net sales growth and low to mid single digit adjusted EBITDA growth, citing elevated inflation, operations investment, and quality plan spend, with a return to EBITDA growth at or above sales growth expected in 2028.
Key takeaways
- Third quarter net sales increased 10% to $7.9 billion, driven almost entirely by organic growth with minimal foreign currency impact.
- Medline Brand segment net sales grew 7% to $3.6 billion with growth across all three product categories, while Supply Chain Solutions grew 14% to $4.2 billion.
- The company is confident in reaching its full year goal of $1 billion in total new customer signings, following a record $2.4 billion signed in 2025.
- A restructuring program was launched to streamline the organizational structure, with expected restructuring costs of $20 million to $30 million recorded in the fourth quarter and excluded from adjusted EBITDA.
- Medline announced a newly authorized $1 billion share repurchase program, its first ever, and prepaid a $750 million term loan in October.
Financial highlights
- Third quarter net sales were $7.9 billion, up 10% year over year, driven almost entirely by organic growth.
- Third quarter adjusted EBITDA rose 12% to $1 billion and margin increased 10 basis points to 12.2%.
- Supply Chain Solutions adjusted EBITDA margin was 4.4% in the quarter due to customer mix and higher operating expenses.
- Free cash flow was $1.8 billion for the first nine months of the year, with cash and short term investments of $3.6 billion and net leverage of 2.5x.
Guidance
- Full year 2026 organic sales guidance was raised to 10% to 10.5% from 9% to 10%.
- Full year 2026 adjusted EBITDA guidance was reaffirmed at $3.3 billion to $3.4 billion, with the company expecting to land at approximately the midpoint.
- The preliminary 2027 framework calls for high single digit net sales growth and adjusted EBITDA growth in the low to mid single digits.
- Adjusted EBITDA growth is expected to return to at or above net sales growth in 2028.
Q&A themes
- Analysts pressed on 2027 margin pressure and the magnitude of inflation, with Middle East conflict cost estimates raised from $70 million to $80 million for 2026 and assumed to persist through 2027.
- Pricing was a recurring topic; management said a larger than usual price increase is planned early in the first quarter of 2027 to offset a portion of COGS inflation, with notification 30 to 60 days in advance.
- Supply Chain Solutions margin drew multiple questions after coming in at 4.4% versus prior expectations, driven by first-year rebates on new prime vendor business and higher operating expenses.
- The global quality action plan was discussed, including the home care bed exit of roughly $60 million and the multiyear third-party assessments across more than 30 manufacturing sites.
Risks
- Inflation tied to elevated oil prices increased the estimated Middle East conflict costs from $70 million to $80 million for 2026, and the company now assumes elevated costs through all of 2027.
- Customer mix toward lower-margin prime vendor relationships and segment mix as Supply Chain Solutions outgrows the higher margin Medline Brand are pressuring margins.
- Costs related to the Tracy, California distribution center fire reduced third quarter net income by $80 million and are excluded from adjusted EBITDA.
FY2026 Q22026-08-05
Earnings calls
AI summary
mixedMedline reported second quarter 2026 net sales of $7.7 billion, up 12% year-over-year, with adjusted EBITDA of $1.1 billion, up 13%, including a $243 million net IEEPA tariff refund benefit. The company raised its full year organic sales guidance for the second time this year to 9% to 10% from 8.5% to 9.5%, citing strong demand and commercial execution. At the same time, it lowered full year adjusted EBITDA guidance to $3.3 billion to $3.4 billion from $3.5 billion to $3.6 billion, citing Middle East conflict costs, the Tracy warehouse fire, growth-related operational investments, quality remediation efforts and retail softness. Management said roughly half of the incremental earnings impact is transitory and half is more permanent, and reaffirmed its long-term objective of growing earnings at or above sales growth.
Key takeaways
- Second quarter net sales rose 12% to $7.7 billion, with Supply Chain Solutions up 16% and Medline Brand up 7%.
- New customer signings exceeded $650 million in the first half, more than 65% of the $1 billion annual goal, and management expressed confidence in reaching $1 billion or more.
- The mid-June Tracy, California distribution center fire reduced net income by $336 million, excluded from adjusted EBITDA, and Medline secured 1.6 million square feet across two new Northern California distribution centers.
- Medline modified its complaint review process, which is expected to increase medical device reporting submissions in the second half of the year.
- Free cash flow was $920 million in the first six months, and net leverage fell to 2.9x, meeting the long-term goal of less than 3x.
Financial highlights
- Second quarter net sales were $7.7 billion, up 12% year-over-year, with IEEPA tariff customer repayments reducing growth by about 1 percentage point.
- Second quarter adjusted EBITDA was $1.1 billion, up 13%, including $243 million of net IEEPA tariff refund benefits; excluding that benefit, underlying adjusted EBITDA was $817 million.
- Adjusted EBITDA margin rose 20 basis points to 13.8% in the second quarter.
- First half net sales were $15 billion, up 11%, and first half free cash flow was $920 million.
Guidance
- Full year 2026 organic sales guidance raised to 9% to 10% from 8.5% to 9.5%, including $89 million of IEEPA tariff refunds planned to be provided to customers.
- Full year 2026 adjusted EBITDA guidance lowered to $3.3 billion to $3.4 billion from $3.5 billion to $3.6 billion, excluding IEEPA tariff refunds received or expected.
- Full year 2026 net tariff impacts estimated at approximately $350 million, down $140 million from the $490 million previously provided.
- CapEx guidance updated to $500 million to $600 million to account for the Tracy fire, and tax distributions narrowed to $250 million to $300 million.
Q&A themes
- Analysts pressed on the composition of the roughly $200 million of incremental costs, with management estimating about 25% external, 75% internal, and roughly half transitory versus permanent.
- Questions focused on customer signings momentum toward the $1 billion annual goal and the pipeline of larger potential wins.
- Several questions addressed tariff refund accounting, including the $507 million total refund, $240 million net benefit recorded in the first half and the roughly $90 million customer repayment accrual.
- Analysts asked about the retail channel softness, which management attributed to losing a portion of one customer due to sales execution rather than overall retail market weakness.
Risks
- Cost headwinds from the Middle East conflict, Tracy fire, operational investments, quality remediation and retail softness led to a lower adjusted EBITDA outlook.
- Some recalled products, including CHG wipes manufactured at the Waukegan facility, are taking longer than expected to return to market, causing earnings loss.
- Medline expects increased medical device reporting submissions in the second half following changes to its complaint review process, and is engaging with the FDA on its global quality action plan.
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 21, 2026, 09:06 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Chief executive
- James Boyle
- Employees
- 45,000
- IPO date
- Dec 17, 2025
- Country
- US
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 3/5
- Return on assetsi
- 4/5
- Debt to equityi
- 1/5
- Price to earningsi
- 1/5
- Price to booki
- 3/5
Company press releases
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.03% | 14.3M |
| FCNKX | 0.28% | 13.3M |
| VO | 0.18% | 12.2M |
| VXF | 0.2% | 5.7M |
| VTV | 0.07% | 5.5M |
| FLBL | 0.59% | 4.5M |
| VWUAX | 0.29% | 3.8M |
| VOE | 0.29% | 3.6M |
| FLCNX | 0.31% | 3.4M |
| FSMAX | 0.21% | 2.1M |
| IWR | 0.13% | 1.9M |
| FNITX | 0.26% | 1.9M |
Analyst track record
How the analysts covering MDLN have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 135 | 136 |
| Analysts | 29 | 29 |
| Buy / hold / sell | 124 / 11 / 0 | 125 / 11 / 0 |
| Upgrades / downgrades / initiations | 0 / 0 / 26 | 0 / 0 / 26 |
| Price targets hit / missed | 5 / 115 (4%) | 5 / 116 (4%) |
| Avg. return after a rating (TipRanks) | -19.6% | -19.6% |
| Best / worst call | +15.2% / -36.8% | +15.2% / -36.8% |
After buy calls on this stock: median 21-day move -0.2% vs S&P 500 -0.5% (n = 110)
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 20, 2026 | Glen SantangeloBarclaysNov 20, 2026 | BuyMaintained | $45.00↗ | article ↗ |
| Nov 13, 2026 | Ivan FeinsethTigress FinancialNov 13, 2026 | BuyReiterated | $55.00↗ | article ↗ |
| Nov 12, 2026 | Lisa GillJ.P. MorganNov 12, 2026 | BuyMaintained | $47.00↗ | article ↗ |
| Nov 11, 2026 | Ryan HalstedRBC CapitalNov 11, 2026 | BuyReiterated | $46.00↗ | article ↗ |
| Nov 9, 2026 | Andrew ObinBank of America SecuritiesNov 9, 2026 | BuyMaintained | –↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 135 ratings
Frequently asked questions
Where can I trade MDLN perpetual futures?
Medline Inc. (MDLN) perpetual futures trade on one crypto venue: MEXC. PerpEquities shows its live price, funding rate, open interest and liquidity.
Can I trade MDLN around the clock?
Yes. Unlike the underlying stock, MDLN perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on MDLN perpetuals?
Right now the MDLN perp funding rate is +21.9% annualized (one venue). A positive rate means longs pay shorts. PerpEquities shows the live rate and its history.
How does the MDLN perp price compare to the Medline Inc. stock?
The venue-median MDLN perp mark is $37.6 versus a reference stock price of $37.6, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a MDLN perpetual future?
A MDLN perpetual is a derivative that tracks the price of Medline Inc. with no expiry date. It lets you take long or short exposure to Medline Inc. on crypto venues, around the clock.
What is MDLNUSDT perpetual?
MDLNUSDT is the symbol most crypto exchanges use for the Medline Inc. perpetual settled in USDT (Tether). It tracks the MDLN share price through an index, trades 24/7 with leverage and never expires.
MEXC